Related Links
Alpha-1 as Seen
on PBS
Watch the PBS show about Alpha-1.
ARALAST NP AATmosphere Program
Support for Alphas and families from the ARALAST NP AATmosphere program.
Real People Archive
Living with Alpha-1 can pose challenges. For many Alphas, sharing experiences and ideas with other Alphas can be helpful in successfully dealing with these challenges.
Each Alpha has a unique story to tell. We trust you'll find these real stories informative and encouraging. Check back often for more real stories from real people with Alpha-1.
Annie Garcia
Annie Garcia, a noted Hispanic professional, is back to work and back to an active lifestyle.
Meet Annie Garcia
Jan Jenkins
Alpha-1 Forced Her to Cut Back on Hiking, Mountain Biking, and Tennis, But Now She's Back in Action
Meet Jan Jenkins
John Bradley
At His Sister's Insistence, He Was Tested for Genetic Emphysema, Now They Run Local Support Group
Meet John Bradley
Cindy Karns
Correctly Diagnosed at Last, Single Mother Determined to Educate Others About Hereditary Emphysema
Meet Cindy Karns
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Important Risk Information for ARALAST NP
ARALAST NP is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The recommended rate of administration (≤ 0.08mL/kg/min) should be closely followed and vital signs monitored continuously. If anaphylactic or severe anaphylactic reactions occur, the infusion should be discontinued immediately.
Safety and effectiveness in patients over age 65 years of age have not been established.
ARALAST NP should be administered at room temperature within three (3) hours after reconstitution and should be administered alone, without mixing with other agents or diluting solutions.
The safety of ARALAST NP was evaluated with ARALAST in a crossover clinical PK comparability study. The most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In the ARALAST pivotal study, the most common adverse events were headache and somnolence.
Please see ARALAST NP Prescribing Information for full prescribing details.
